Presentation synopsis:
The T cell component: Induction of potent CD8+ T cell responses for HIV cure
In this study, we aimed at understanding the impact of HIV infection on the induction of CD8+ T-cells and at investigating potential factors to enhance this process. We evaluated the capacity of HIV-1 treated patients to induce new CD8+ T-cell responses, and compared the priming capacity of HIV-1 and HIV-2 viruses in vitro. The priming of antigen-specific CD8+ T-cells is reduced in HIV-1 infected individuals, and correlates with naive CD8+ T cell availability. Interestingly, HIV-2 induces stronger expansion of robust CD8+ T cells, which express genes related to effector functions, survival and type I IFN pathway induction.
Besides, the use of an IFN related adjuvant, the STING ligand cGAMP, potentiates the priming capacity of CD8+ T cells from HIV-1 infected persons, which may have direct relevance for therapeutic strategies.
Speaker:
Mariela Piccin, France
